Mandate

Vinge advises Axcel and XPartners in connection with the acquisition of P O Andersson

February 14, 2024 M&A Real Estate and Construction

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of P O Andersson Konstruktionsbyrå Aktiebolag AB (”P O Andersson”).

P O Andersson employs approximately 20 civil, university and high school engineers and conducts engineering consultancy operations. The assignments mainly include design of facilities for various systems, such as air conditioning, cooling, heating, water and sewage, as well as framework documents for control and monitoring and sprinkler systems. P O Andersson was established over 40 years ago and has extensive experience in planning and designing various types of building projects and works with commercial and public sector premises, industries, energy centres and residential construction.

Vinge's team consisted of partner Christina Kokko together with Karl Klackenberg, Carl Fredrik Wachtmeister, Gustav Persson, Egil Svensson, Sara Passandideh, Filip Magnusson and Alexander Rüdén (M&A), Clara Klingspor (Construction) and Cecilia Loctander (Transaction Support Co-ordinator).

 

 

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025